DisGeNET is a knowledge management platform that integrates and standardizes the data of genes and mutations related to diseases from multiple sources. It covers entire range of human disease.
Source | Last Updated |
---|---|
DisGeNET | July 29, 2024 |
Disease ID | Disease Name | Gene Symbol | Gene ID ▲ | Gene Name | UniProt ID |
---|---|---|---|---|---|
C0206754 | Neuroendocrine Tumors | DAD1 | 1603 | defender against cell death 1 | P61803 |
C0264408 | Childhood asthma | DAD1 | 1603 | defender against cell death 1 | P61803 |
C0149925 | Small cell carcinoma of lung | DAD1 | 1603 | defender against cell death 1 | P61803 |
C1306459 | Primary malignant neoplasm | DAD1 | 1603 | defender against cell death 1 | P61803 |
C0004763 | Barrett Esophagus | DAD1 | 1603 | defender against cell death 1 | P61803 |
C0155877 | Allergic asthma | DAD1 | 1603 | defender against cell death 1 | P61803 |
C0006826 | Malignant Neoplasms | DAD1 | 1603 | defender against cell death 1 | P61803 |
C0018784 | Sensorineural Hearing Loss (disorder) | TMTC2 | 160335 | transmembrane O-mannosyltransferase targeting cadherins 2 | Q8N394 |
C0152136 | Low Tension Glaucoma | TMTC2 | 160335 | transmembrane O-mannosyltransferase targeting cadherins 2 | Q8N394 |
C0017601 | Glaucoma | TMTC2 | 160335 | transmembrane O-mannosyltransferase targeting cadherins 2 | Q8N394 |
C0013595 | Eczema | TMTC2 | 160335 | transmembrane O-mannosyltransferase targeting cadherins 2 | Q8N394 |
C0004096 | Asthma | TMTC2 | 160335 | transmembrane O-mannosyltransferase targeting cadherins 2 | Q8N394 |
C4082305 | Deaf Mutism | TMTC2 | 160335 | transmembrane O-mannosyltransferase targeting cadherins 2 | Q8N394 |
C0339573 | Glaucoma, Primary Open Angle | TMTC2 | 160335 | transmembrane O-mannosyltransferase targeting cadherins 2 | Q8N394 |
C0011053 | Deafness | TMTC2 | 160335 | transmembrane O-mannosyltransferase targeting cadherins 2 | Q8N394 |
C0023467 | Leukemia, Myelocytic, Acute | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C0023465 | Acute monocytic leukemia | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C0023473 | Myeloid Leukemia, Chronic | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C1332977 | Childhood Leukemia | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C0021053 | Immune System Diseases | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C0023418 | leukemia | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C0014070 | Encephalomyelitis | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C1306459 | Primary malignant neoplasm | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C0026946 | Mycoses | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
C0026470 | Monoclonal Gammopathy of Undetermined Significance | CLEC12A | 160364 | C-type lectin domain family 12 member A | Q5QGZ9 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024